A Review of Daclatasvir Drug –Drug Interactions

This article presents an overview of the drug interaction studies conducted during the clinical development of DCV, the findings of these studies that led to the guidance on concomitant medication use and dosage along with any required DCV dose modifications, and th e use of the known metabolic pathway of DCV to guide concomitant dosing where direct drug–drug studies have not been conducted. The robust characterization of the DCV clinical pharmacology program has demonstrated that DCV has few or no clinically relevant DDIs with medications with which it is li kely to be co-administered, and the majority of DDIs that do occur can be predicted and easily managed.Funding: Bristol-Myers Squibb.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research